Peter J. Reddig

Array ( [id] => 12702418 [patent_doc_number] => 20180125972 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-10 [patent_title] => MULTIPLE ANTIGEN BINDING MOLECULAR FUSION, PHARMACEUTICAL COMPOSITION, METHOD FOR IDENTIFYING LINEAR EPITOPE, AND METHOD FOR PREPARING MULTIPLE ANTIGEN BINDING MOLECULAR FUSION [patent_app_type] => utility [patent_app_number] => 15/573154 [patent_app_country] => US [patent_app_date] => 2016-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23579 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15573154 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12663895 [patent_doc_number] => 20180113131 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-26 [patent_title] => METHOD OF PREDICTING EFFECT OF TREATMENT BY PD-1/PD-L1 BLOCKADE USING ABNORMALITY OF PD-L1 (CD274) AS INDEX [patent_app_type] => utility [patent_app_number] => 15/569898 [patent_app_country] => US [patent_app_date] => 2016-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10344 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15569898 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12637434 [patent_doc_number] => 20180104308 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-19 [patent_title] => CD5 CHIMERIC ANTIGEN RECEPTOR FOR ADOPTIVE T CELL THERAPY [patent_app_type] => utility [patent_app_number] => 15/568702 [patent_app_country] => US [patent_app_date] => 2016-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19805 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -75 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15568702 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11443202 [patent_doc_number] => 20170044223 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-16 [patent_title] => 'Human Sperm Fibrous Sheath (FS) Proteins: New Target Antigens For Use In Therapeutic Cancer Vaccines And Diagnostic Screening And Methods Of Using Same' [patent_app_type] => utility [patent_app_number] => 15/094726 [patent_app_country] => US [patent_app_date] => 2016-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3724 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15094726 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11336724 [patent_doc_number] => 20160362472 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-15 [patent_title] => 'CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR)- EXPRESSING CELL' [patent_app_type] => utility [patent_app_number] => 15/094674 [patent_app_country] => US [patent_app_date] => 2016-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 119 [patent_figures_cnt] => 119 [patent_no_of_words] => 184889 [patent_no_of_claims] => 48 [patent_no_of_ind_claims] => 22 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15094674 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16028765 [patent_doc_number] => 10676792 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-09 [patent_title] => Prognostic and diagnostic methods for colorectal cancer [patent_app_type] => utility [patent_app_number] => 15/563493 [patent_app_country] => US [patent_app_date] => 2016-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 21219 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15563493 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13885481 [patent_doc_number] => 10195272 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-05 [patent_title] => Adoptive t-cell therapy using FceRI-based chimeric antigen receptors for treating IgE-mediated allergic diseases [patent_app_type] => utility [patent_app_number] => 15/084192 [patent_app_country] => US [patent_app_date] => 2016-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 12 [patent_no_of_words] => 18327 [patent_no_of_claims] => 81 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15084192 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11403043 [patent_doc_number] => 20170023577 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-26 [patent_title] => 'METHODS FOR THE IDENTIFICATION, ASSESSMENT, AND TREATMENT OF PATIENTS WITH PROTEASOME INHIBITION THERAPY' [patent_app_type] => utility [patent_app_number] => 15/080709 [patent_app_country] => US [patent_app_date] => 2016-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56764 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15080709 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11090730 [patent_doc_number] => 20160287699 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-06 [patent_title] => 'FGFR/PD-1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER' [patent_app_type] => utility [patent_app_number] => 15/079136 [patent_app_country] => US [patent_app_date] => 2016-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 9847 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15079136 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16954895 [patent_doc_number] => 11058722 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-13 [patent_title] => Chimeric antigen receptor comprising a cartilage-oligomeric matrix protein (comp) coiled-coil spacer domain [patent_app_type] => utility [patent_app_number] => 15/560558 [patent_app_country] => US [patent_app_date] => 2016-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 13280 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15560558 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16954895 [patent_doc_number] => 11058722 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-13 [patent_title] => Chimeric antigen receptor comprising a cartilage-oligomeric matrix protein (comp) coiled-coil spacer domain [patent_app_type] => utility [patent_app_number] => 15/560558 [patent_app_country] => US [patent_app_date] => 2016-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 13280 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15560558 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17586580 [patent_doc_number] => 11324822 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-10 [patent_title] => Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer [patent_app_type] => utility [patent_app_number] => 15/559402 [patent_app_country] => US [patent_app_date] => 2016-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12023 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15559402 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12185493 [patent_doc_number] => 20180044429 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-15 [patent_title] => 'CD27 AGONISTS' [patent_app_type] => utility [patent_app_number] => 15/557035 [patent_app_country] => US [patent_app_date] => 2016-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 27358 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15557035 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11948284 [patent_doc_number] => 20170252435 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-07 [patent_title] => 'Combination' [patent_app_type] => utility [patent_app_number] => 15/060071 [patent_app_country] => US [patent_app_date] => 2016-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 15107 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15060071 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13793361 [patent_doc_number] => 20190010219 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-10 [patent_title] => Conditionally Active Chimeric Antigen Receptors for Modified T-Cells [patent_app_type] => utility [patent_app_number] => 15/753872 [patent_app_country] => US [patent_app_date] => 2016-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41387 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15753872 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10822106 [patent_doc_number] => 20160168270 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-16 [patent_title] => 'PREVENTION AND TREATMENT OF PAIN USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID' [patent_app_type] => utility [patent_app_number] => 15/047612 [patent_app_country] => US [patent_app_date] => 2016-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 28219 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15047612 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16605980 [patent_doc_number] => 10906972 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-02 [patent_title] => Cancer cell specific anti-podocalyxin antibody and method for producing same [patent_app_type] => utility [patent_app_number] => 15/549923 [patent_app_country] => US [patent_app_date] => 2016-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 7 [patent_no_of_words] => 15391 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15549923 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10813744 [patent_doc_number] => 20160159904 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-09 [patent_title] => 'CANCER STEM CELL-SPECIFIC MOLECULE' [patent_app_type] => utility [patent_app_number] => 15/042548 [patent_app_country] => US [patent_app_date] => 2016-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 74 [patent_figures_cnt] => 74 [patent_no_of_words] => 44171 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15042548 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18604709 [patent_doc_number] => 11746159 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-05 [patent_title] => Humanized anti-MUC1* antibodies [patent_app_type] => utility [patent_app_number] => 15/549942 [patent_app_country] => US [patent_app_date] => 2016-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 62 [patent_figures_cnt] => 62 [patent_no_of_words] => 33722 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15549942 [rel_patent_id] =>[rel_patent_doc_number] =>)